Lehrke Ingo, Waldherr Rüdiger, Ritz Eberhard, Wagner Jürgen
Department of Nephrology, University of Heidelberg, Germany.
J Am Soc Nephrol. 2001 Nov;12(11):2321-2329. doi: 10.1681/ASN.V12112321.
The endothelin (ET) system has been studied extensively in experimental models of progressive chronic renal disease, but there is limited information regarding the ET system in renal patients. First, the expression of human ET-1, as well as ET receptor type A (ET-R(A)) and ET-R(B), was studied in 26 renal biopsies from patients with different renal diseases. Gene expression was assessed by quantitative reverse transcription-PCR. Second, ET-1 and ET-R(B) protein expression and localization were examined, by immunohistochemical analyses, among a homogeneous cohort of 16 patients with IgA nephropathy and different degrees of proteinuria. ET-R(B) mRNA expression was threefold higher among patients with higher-grade proteinuria [> or =2 g/24 h, n = 10; OD ratio (ODR), i.e., wild-type/mutant mRNA ratio, 1.81 +/- 0.3], compared with patients with lower-grade proteinuria (<2 g/24 h, n = 8; ODR, 0.63 +/- 0.1; P < 0.01) or control subjects (n = 9; ODR, 0.57 +/- 0.1; P < 0.01). ET-1 gene expression was significantly higher among patients with higher-grade proteinuria, compared with patients with lower-grade proteinuria (P < 0.01) or control subjects (P < 0.05). ET-R(A) mRNA expression was not different among the groups. Patients with higher-grade proteinuria who were receiving angiotensin-converting enzyme inhibitors exhibited significantly (P < 0.05) lower ET-1 and ET-R(B) mRNA expression, which was comparable to that of control subjects. By using immunohistochemical analyses, an association between proteinuria and expression of ET-1 and ET-R(B) in proximal tubular epithelial cells and of ET-1 in glomeruli was confirmed in the separate cohort of patients with IgA nephropathy. It is concluded that the increased ET-R(B) and ET-1 mRNA and protein expression observed in animal models of renal disease is also demonstrable among patients with renal disease and high-grade proteinuria.
内皮素(ET)系统已在进行性慢性肾病的实验模型中得到广泛研究,但关于肾病患者ET系统的信息有限。首先,在26例患有不同肾病的患者肾活检组织中研究了人ET-1以及A型ET受体(ET-R(A))和B型ET受体(ET-R(B))的表达。通过定量逆转录聚合酶链反应评估基因表达。其次,通过免疫组织化学分析,在16例患有IgA肾病且蛋白尿程度不同的同质队列患者中检测ET-1和ET-R(B)蛋白表达及定位。与蛋白尿程度较低的患者(<2 g/24 h,n = 8;OD比值(ODR),即野生型/突变型mRNA比值,0.63±0.1)或对照组(n = 9;ODR,0.57±0.1)相比,蛋白尿程度较高的患者(≥2 g/24 h,n = 10;ODR,1.81±0.3)中ET-R(B) mRNA表达高3倍(P<0.01)。与蛋白尿程度较低的患者(P<0.01)或对照组(P<0.05)相比,蛋白尿程度较高的患者中ET-1基因表达显著更高。各组间ET-R(A) mRNA表达无差异。接受血管紧张素转换酶抑制剂治疗的蛋白尿程度较高的患者,其ET-1和ET-R(B) mRNA表达显著降低(P<0.05),与对照组相当。通过免疫组织化学分析,在另一组IgA肾病患者中证实了蛋白尿与近端肾小管上皮细胞中ET-1和ET-R(B)表达以及肾小球中ET-1表达之间的关联。结论是,在肾病动物模型中观察到的ET-R(B)和ET-1 mRNA及蛋白表达增加在肾病和重度蛋白尿患者中也得到证实。